ESMO Gastrointestinal Oncology

Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER

Pub Date : 2024-12-01 DOI: 10.1016/j.esmogo.2024.100114 E. Smyth , D. Griffiths , K. Cozens , S. Ewings , R. Waugh , R.C. Turkington , K. Foley , R. Roy , S. Ngan , R. Owen , D. Chuter , C. Steele , G. Griffiths

PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials

Pub Date : 2024-11-27 DOI: 10.1016/j.esmogo.2024.100107 A. Cammarota , S.K. Kamarajah , S. Markar , E.C. Smyth

Practical management of oligometastatic gastric cancer

Pub Date : 2024-11-21 DOI: 10.1016/j.esmogo.2024.100108 Y. Narita , K. Muro , D. Takahari